Skip to content

EVALUATION OF THE EFFECT OF THE PERFECTA V-BEAM LASER ON ROSACEA

EVALUATION OF THE EFFECT OF THE PERFECTA V-BEAM LASER ON ROSACEA (FACIAL REDNESS, TELANGIECTASIAS AND PHOTODAMAGE)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03211585
Enrollment
20
Registered
2017-07-07
Start date
2016-10-31
Completion date
2018-12-31
Last updated
2017-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea

Brief summary

The purpose of this study is to further quantify the safety and effectiveness of the Syneron-Candela long pulse-duration, extended sub-pulse, larger spot-size prototype Perfecta V-Beam, 595nm laser system for the treatment of facial redness associated with flushing and blushing, or rosacea. The Perfecta laser system is expected to provide effective treatment of rosacea with less bruising or purpura and greater effectiveness than previous generation systems. This study should enable optimization of treatment parameters for using the Perfecta 595nm laser for treating rosacea.

Interventions

DEVICEPerfecta V-Beam laser

This s a single study and a prototype of the FDA-cleared, flashlamp-pumped pulsed-dye laser, that is currently on the market, that has evolved over almost 25 years of continuous development. The broad-spectrum flashlamp pumps energy into a cavity containing liquid dye. The dye is excited resulting in the emission of 595 nm orange light.

Sponsors

Syneron Medical
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Subjects must have a Fitzpatrick skin type of I-IV and have Rosacea as evaluated by the treating physician. * Subjects must have visible telangiectasia on the side of the face. * Subjects must be willing and able to comply with all follow-up requirements. * Subjects must be willing and able to apply sunblock SPF of 30 while exposed to the sun. * Subject willing to have photographs taken and used in presentations or publications.

Exclusion criteria

* Subjects must not have had a previous laser treatment, deep chemical peel in the intended treatment site(s) within 6 months prior to treatment, oral retinoids within 6 months of their inclusion into this study or have ever taken gold therapy. * Subjects must not have a history of keloid formation. * Subjects with Fitzpatrick Classification of V or VI (to reduce the risk of hyper-pigmentation). * Subjects must be willing and able to comply with all follow-up requirements. * Subjects cannot have vitiligo, a condition where pigment is lost in the skin and white patches appear). * Subjects not willing to avoid sun exposure or not will to apply sunblock SPF of 30 while exposed to the sun. * Subject not willing to have photographs taken and used in presentations, publications and marketing material

Design outcomes

Primary

MeasureTime frameDescription
The percentage reduction in the facial redness and telangiectasias of rosaceatwo months following the final treatmentThe percentage reduction in the facial redness and telangiectasias of rosacea will be determined by the investigators using polarized photography for each subject

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026